Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels. 1991

V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
Third Medical Department, Medical Faculty of the Palacký University, Olmouc, CSFR.

In 71 patients with multiple myeloma the authors evaluated the clinical significance and the prognostic relevance of Bataille's stratification system based on serum beta 2-microglobulin and serum albumin levels. This staging system, which classified the patients to low, intermediate and poor risk groups (stages 1-3) showed a rather small prognostic significance, and it stratified our myeloma patients unsatisfactorily. On the basis of the results of our own analyses, we have developed our own modification of a pilot stratification system. We have verified its good clinical applicability and its powerful prognostic prediction. In this study, the good prognostic significance of serum beta 2-microglobulin and albumin levels (with the best cut-off levels of 4.0 mg/l and 35.0 g/l) and a good correlation between both analysed markers were confirmed.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D001613 beta 2-Microglobulin An 11-kDa protein associated with the outer membrane of many cells including LYMPHOCYTES. It is the small subunit of MHC CLASS I MOLECULES. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, CEREBROSPINAL FLUID, and urine of healthy individuals, and to a much greater degree in the urine and plasma of patients with tubular PROTEINURIA, renal failure, or kidney transplants. Thymotaxin,beta 2 Microglobulin
D012709 Serum Albumin A major protein in the BLOOD. It is important in maintaining the colloidal osmotic pressure and transporting large organic molecules. Plasma Albumin,Albumin, Serum
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival

Related Publications

V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
August 1986, British journal of haematology,
V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
October 1983, European journal of cancer & clinical oncology,
V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
January 1986, British journal of haematology,
V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
January 1982, Acta medica Austriaca,
V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
March 1981, Revue du rhumatisme et des maladies osteo-articulaires,
V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
January 1987, Anticancer research,
V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
January 1991, Life sciences,
V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
December 1987, European journal of cancer & clinical oncology,
V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
January 1984, Acta haematologica Polonica,
V Scudla, and M Budíková, and E Fischerová, and J Zadrazil, and K Indrák
January 2004, The Central African journal of medicine,
Copied contents to your clipboard!